Kenny Wilson Acquires 199 Shares of Dr. Martens plc (LON:DOCS) Stock

Dr. Martens plc (LON:DOCSGet Free Report) insider Kenny Wilson bought 199 shares of the stock in a transaction dated Wednesday, December 11th. The stock was acquired at an average price of GBX 76 ($0.96) per share, with a total value of £151.24 ($190.89).

Kenny Wilson also recently made the following trade(s):

  • On Thursday, September 26th, Kenny Wilson acquired 30,000 shares of Dr. Martens stock. The stock was bought at an average price of GBX 55 ($0.69) per share, with a total value of £16,500 ($20,825.44).

Dr. Martens Trading Down 0.6 %

Shares of DOCS opened at GBX 76.55 ($0.97) on Friday. The firm has a market capitalization of £736.20 million, a PE ratio of 1,093.57, a price-to-earnings-growth ratio of 6.40 and a beta of 0.11. Dr. Martens plc has a 12-month low of GBX 49.32 ($0.62) and a 12-month high of GBX 100 ($1.26). The company has a quick ratio of 1.13, a current ratio of 2.85 and a debt-to-equity ratio of 129.55. The stock’s fifty day simple moving average is GBX 59.81 and its 200-day simple moving average is GBX 67.37.

Dr. Martens Cuts Dividend

The firm also recently disclosed a dividend, which will be paid on Tuesday, April 8th. Investors of record on Thursday, March 6th will be issued a GBX 0.85 ($0.01) dividend. The ex-dividend date of this dividend is Thursday, March 6th. This represents a yield of 1.47%. Dr. Martens’s dividend payout ratio is currently 4,285.71%.

Dr. Martens Company Profile

(Get Free Report)

Dr. Martens plc designs, develops, procures, markets, sells, and distributes footwear in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It offers originals, fusion, kids, and casual, as well as accessories. The company offers its products under the Dr. Martens brand name. Dr. Martens plc was founded in 1945 and is based in London, the United Kingdom.

See Also

Insider Buying and Selling by Quarter for Dr. Martens (LON:DOCS)

Receive News & Ratings for Dr. Martens Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Martens and related companies with MarketBeat.com's FREE daily email newsletter.